1. Others
  2. Drug Derivative
  3. IBI352g4a

IBI352g4a is a humanized IgG1 monoclonal antibody targeting PVRIG (Kd = 0.53 nM) and acts as a PVRIG/PVRL2 inhibitor. The anti-tumor effect of IBI352g4a depends on the binding of its Fc region to FcγR. IBI352g4a binds to the extracellular domains of human and cynomolgus monkey PVRIG, and blocks the PVRIG-PVRL2 interaction. IBI352g4a induces NK cell activation, promotes their degranulation and tumor killing. IBI352g4a can be used in the research of gastric cancer.

For research use only. We do not sell to patients.

IBI352g4a

IBI352g4a Chemical Structure

Size Stock
1 mg   Get quote  
5 mg   Get quote  
10 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Top Publications Citing Use of Products
  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

IBI352g4a is a humanized IgG1 monoclonal antibody targeting PVRIG (Kd = 0.53 nM) and acts as a PVRIG/PVRL2 inhibitor. The anti-tumor effect of IBI352g4a depends on the binding of its Fc region to FcγR. IBI352g4a binds to the extracellular domains of human and cynomolgus monkey PVRIG, and blocks the PVRIG-PVRL2 interaction. IBI352g4a induces NK cell activation, promotes their degranulation and tumor killing. IBI352g4a can be used in the research of gastric cancer[1].

Species Reactivity

Human

In Vitro

IBI352g4a binds recombinant human PVRIG with high affinity, with a Kd of 0.53 nM[1].
IBI352g4a binds recombinant cynomolgus monkey PVRIG with a Kd of 2.71 nM[1].
IBI352g4a binds human PVRIG-overexpressing GS-CHO cells in a dose-dependent manner, with an EC50 of 2.03 nM[1].
IBI352g4a binds cynomolgus monkey PVRIG-overexpressing GS-CHO cells in a dose-dependent manner, with an EC50 of 7.42 nM[1].
IBI352g4a completely blocks the interaction between human PVRIG and PVRL2, with an IC50 of 0.94 nM[1].
IBI352g4a (10 μg/mL; 4 h) significantly increases degranulation (CD107a expression) in purified human NK cells cocultured with K562 cells for 4 h[1].
IBI352g4a (10 μg/mL; 16 h) significantly increases activation (CD137 expression) in purified human NK cells cocultured with K562 cells for 16 h[1].
IBI352g4a (10 μg/mL; 5 h) significantly increases NK cell-mediated killing of CTV-labeled K562 cells[1].
IBI352g4a (10 ng/mL-10 μg/mL; 4 h) induces dose-dependent NK cell-mediated killing of K562 cells, with an EC50 of 0.075 nM after 4 h of coculture[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cytotoxicity Assay[1]

Cell Line: purified human NK cells, CellTrace Violet (CTV)-labeled K562 tumor cells
Concentration: 10 μg/mL
Incubation Time: 5 h
Result: Significantly increased the percentage of PI+ CTV+ dead K562 cells compared to control IgG treatment.

Cell Cytotoxicity Assay[1]

Cell Line: NK cells, K562 cells
Concentration: 10-8, 10-6, 10-4, 10-2, 100, 102 μg/mL
Incubation Time: 4 h
Result: Induced dose-dependent NK cell-mediated killing of K562 cells, with an EC50 of 0.075 nM after 4 h of coculture.
In Vivo

IBI352g4a (10 mg/kg; i.p.; 6 doses on days 7-24) exerts potent dose-dependent antitumor efficacy against human gastric cancer in immune-reconstituted B-NDG hIL15 mice[1].
IBI352g4a (10 mg/kg; i.p.; 6 doses on days 5-22) has limited antitumor efficacy against human gastric cancer in T-cell-only reconstituted NOG mice, indicating NK cells are critical for its optimal activity[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: B-NDG hIL15 mice[1]
Dosage: 10 mg/kg
Administration: i.p.; 6 doses on days 7, 10, 13, 17, 20, 24
Result: Reduced mean tumor volume.
Maintained stable body weight throughout treatment.
Animal Model: NOG mice[1]
Dosage: 10 mg/kg
Administration: i.p.; 6 doses on days 5, 8, 11, 15, 18, 22
Result: Showed limited antitumor efficacy, with significantly weaker activity compared to its efficacy in B-NDG hIL15 mice with NK and T cell reconstitution.
Gene ID

79037  [NCBI]

Accession
Target

PVRIG/CD112R

Application

ELISA, FACS, Functional assay

Conjugated

Unconjugated

Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.

Formulation

Please refer to the lot-specific COA for specific buffer information.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

 

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

     

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
IBI352g4a
Cat. No.:
HY-P992381
Quantity:
MCE Japan Authorized Agent: